iifl-logo

Surya Pharmaceutical Ltd Share Price

0.15
(0.00%)
Sep 14, 2015|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Surya Pharmaceutical Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

0.15

Prev. Close

0.15

Turnover(Lac.)

0.45

Day's High

0.2

Day's Low

0.1

52 Week's High

0

52 Week's Low

0

Book Value

-38.52

Face Value

1

Mkt Cap (₹ Cr.)

3.04

P/E

0.01

EPS

12.76

Divi. Yield

0

Surya Pharmaceutical Ltd Corporate Action

No Record Found

Surya Pharmaceutical Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Surya Pharmaceutical Ltd SHAREHOLDING SNAPSHOT

02 Apr, 2025|06:09 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.96%

Foreign: 0.00%

Indian: 0.96%

Non-Promoter- 0.03%

Institutions: 0.02%

Non-Institutions: 99.01%

Custodian: 0.00%

Share Price

Surya Pharmaceutical Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2013Mar-2012Mar-2011Mar-2010

Equity Capital

20.28

20.28

25.84

14.47

Preference Capital

0

0

0

0

Reserves

-74.61

227.2

494.11

288.72

Net Worth

-54.33

247.48

519.95

303.19

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2013Mar-2012Mar-2011

Revenue

60.33

1,622.94

1,600.41

yoy growth (%)

-96.28

1.4

Raw materials

-182.85

-1,654.5

-1,230.99

As % of sales

303.09

101.94

76.91

Employee costs

-8.84

-40.91

-40.35

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2013Mar-2012Mar-2011

Profit before tax

-440.77

-393.22

131.71

Depreciation

-62.46

-34.61

-26.54

Tax paid

156.89

120.06

-31.55

Working capital

-144.38

-295.48

Other operating items

View Cash Flow
Y/e 31 MarMar-2013Mar-2012Mar-2011

Growth matrix (%)

Revenue growth

-96.28

1.4

Op profit growth

1.42

-161.08

EBIT growth

4.27

-199.07

Net profit growth

10.49

-376.16

View Ratios

No Record Found

Surya Pharmaceutical Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceutical Industries Ltd

SUNPHARMA

1,698.35

129.244,07,155.151,181.050.85,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,549.7

71.051,47,295.245940.542,297513.62

Cipla Ltd

CIPLA

1,444.25

25.071,16,664.331,438.150.94,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,183.9

59.031,07,673.274850.882,330222.38

Mankind Pharma Ltd

MANKIND

2,458.1

52.421,01,358.17416.3802,396.57334.17

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Surya Pharmaceutical Ltd

Management

Register Office

Registrar Office

Executive Director

Alka Goyal

Chairman & Managing Director

Rajiv Goyal

Additional Director

Jasvinder Singh

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Surya Pharmaceuticals (Surya) is a Chandigarh-based pharmaceutical company with four manufacturing facilities spread across three states of Himachal Pradesh, Haryana and Punjab. The company produces semi synthetic penicillin based products, first generation cephalosporins, anti histamines, drug intermediaries and formulations. Surya can be considered predominantly a bulk drug or Active Pharmaceutical Ingredient (API) manufacturer, as formulations constituted less than 4% of revenues in FY 2002-03, while the balance was contributed by API, intermediaries and others. Surya Pharmaceuticals is relatively a very small player in the current context. Nevertheless, it has found a space in both domestic and overseas market. In the domestic market, it has opted to become preferred supplier of APIs to domestic pharma majors. In the overseas market, it has been focussing on Far East, Middle East and South Asia. Overall it plans to focus equally on domestic and export market. The company has offered 30 lakh equity shares of Rs 10 each at a premium of Rs 35 each, aggregating Rs 13.50 crore. The issue proceeds will be utilised, predominantly to augment working capital requirements at Rs 10.47 crore, Plant and machinery for R & D amounting to Rs 2.33 crore and for preliminary and public issue expenses of Rs 0.70 crore. Rajeev Goal, who is currently the companys Managing Director, has promoted the company. The core promoters hold 36.41% stake in the company, which will come down to 25.98% pos
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.